Additional file 3: Figure S3. Adjusted risk difference and adjusted odds ratio (OR) for treatment failure for each risk factor from a conservative imputation model. In this model, we assumed all missing SARS-CoV-2 positive test dates were ten days prior to the mAb administration date. Risk differences were calculated via Firth's bias-reduced multiple regression logistic regression. Adjusted ORs and 95% confidence intervals (95% CI) were computed by penalized profile likelihood
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
BACKGROUND: The appropriate handling of missing covariate data in prognostic modelling studies is ye...
International audienceRelative survival assesses the effects of prognostic factors on disease-specif...
Additional file 4: Figure S4. Adjusted risk difference and adjusted odds ratio (OR) for treatment fa...
Additional file 5: Table S1. Medications and conditions used to stratify Mild versus Moderate/Severe...
Additional file 2: Figure S2. Cumulative incidence of hazard for hospitalization by immunocompromise...
Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently...
The rate of prescription of drugs across the inpatient A) The measured effect of COVID-19 incidence ...
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infecti...
Model additionally includes time from preimmunization to serology (i.e., months since last infection...
Background: The aim of this secondary analysis of the TESEO cohort is to identify, early in the cour...
Additional file 1: Table S1. Characteristics of participants with breakthrough infections, post-vacc...
a<p>Multiple imputation was used to adjust for a small amount of missing data on some characteristic...
Model includes type of vaccine and timing of vaccinations between dose 1 and dose 2. (PDF)</p
<p>All models were adjusted for study site. Baseline CD4 cell count and adherence were not significa...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
BACKGROUND: The appropriate handling of missing covariate data in prognostic modelling studies is ye...
International audienceRelative survival assesses the effects of prognostic factors on disease-specif...
Additional file 4: Figure S4. Adjusted risk difference and adjusted odds ratio (OR) for treatment fa...
Additional file 5: Table S1. Medications and conditions used to stratify Mild versus Moderate/Severe...
Additional file 2: Figure S2. Cumulative incidence of hazard for hospitalization by immunocompromise...
Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently...
The rate of prescription of drugs across the inpatient A) The measured effect of COVID-19 incidence ...
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infecti...
Model additionally includes time from preimmunization to serology (i.e., months since last infection...
Background: The aim of this secondary analysis of the TESEO cohort is to identify, early in the cour...
Additional file 1: Table S1. Characteristics of participants with breakthrough infections, post-vacc...
a<p>Multiple imputation was used to adjust for a small amount of missing data on some characteristic...
Model includes type of vaccine and timing of vaccinations between dose 1 and dose 2. (PDF)</p
<p>All models were adjusted for study site. Baseline CD4 cell count and adherence were not significa...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
BACKGROUND: The appropriate handling of missing covariate data in prognostic modelling studies is ye...
International audienceRelative survival assesses the effects of prognostic factors on disease-specif...